Nisa Investment Advisors LLC Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Nisa Investment Advisors LLC trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 20.5% in the 4th quarter, Holdings Channel reports. The fund owned 9,649 shares of the biopharmaceutical company’s stock after selling 2,484 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $3,837,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. OFI Invest Asset Management boosted its stake in Alnylam Pharmaceuticals by 5.8% during the third quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 22 shares in the last quarter. Howard Capital Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2.9% during the third quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock valued at $389,000 after purchasing an additional 24 shares in the last quarter. Frank Rimerman Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 2.0% during the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock valued at $570,000 after purchasing an additional 24 shares in the last quarter. Coastal Bridge Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 2.3% during the third quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock valued at $500,000 after purchasing an additional 25 shares during the last quarter. Finally, Meridian Financial Advisors LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 3.5% during the third quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock valued at $378,000 after purchasing an additional 28 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on ALNY. Freedom Capital upgraded Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. HC Wainwright reiterated a “buy” rating and set a $510.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Raymond James Financial reissued an “outperform” rating and issued a $472.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Wells Fargo & Company cut their target price on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a research note on Tuesday, January 20th. Finally, Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $473.87.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 9,577 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22. Following the transaction, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. This represents a 10.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Pushkal Garg sold 2,242 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the transaction, the executive vice president directly owned 24,848 shares in the company, valued at approximately $7,704,867.84. The trade was a 8.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 53,923 shares of company stock worth $18,072,087 in the last ninety days. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $318.85 on Friday. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The company has a 50 day moving average price of $327.55 and a 200-day moving average price of $396.63. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The firm has a market capitalization of $42.29 billion, a PE ratio of 186.46 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter last year, the company earned ($0.65) EPS. The firm’s revenue for the quarter was up 84.9% on a year-over-year basis. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.